TG Therapeutics IncNASDAQ:TGTX
- LAST PRICE29.6500
- TODAY'S CHANGE (%)0.0400 (0.1351%)
- Bid / Lots29.6500/ 5
- Ask / Lots29.6800/ 2
- Open / Previous Close29.5200 / 29.6100
- Day Range
- 52 Week Range
- Volume344,115
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TGTX |
|---|---|---|
| 09:32 ET | 25482 | 29.58 |
| 09:33 ET | 5300 | 29.8864 |
| 09:35 ET | 4833 | 29.68 |
| 09:37 ET | 5459 | 30 |
| 09:39 ET | 18950 | 30.1 |
| 09:42 ET | 12767 | 29.975 |
| 09:44 ET | 10110 | 30.0245 |
| 09:46 ET | 15643 | 29.875 |
| 09:48 ET | 2407 | 29.85 |
| 09:50 ET | 10777 | 29.9675 |
| 09:51 ET | 52232 | 29.755 |
| 09:53 ET | 9339 | 29.77 |
| 09:55 ET | 23184 | 29.8799 |
| 09:57 ET | 5780 | 30 |
| 10:00 ET | 15777 | 29.95 |
| 10:02 ET | 7576 | 29.71 |
| 10:04 ET | 6928 | 29.7594 |
| 10:06 ET | 5405 | 29.6 |
| 10:08 ET | 9084 | 29.5432 |
| 10:09 ET | 6668 | 29.733 |
| 10:11 ET | 12262 | 29.7 |
| 10:13 ET | 6315 | 29.62 |
| 10:15 ET | 3049 | 29.59 |
| 10:18 ET | 6228 | 29.7 |
| 10:20 ET | 4574 | 29.6925 |
| 10:22 ET | 1100 | 29.685 |
| 10:24 ET | 3633 | 29.65 |
| 10:26 ET | 520 | 29.65 |
Nov 5, 2024
DJ TG Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 12:51PM ET on Tuesday Nov 05, 2024 by Dow Jones
12:51PM ET on Tuesday Nov 05, 2024 by Dow JonesDJ TG Therapeutics Is Maintained at Neutral by Goldman Sachs, from 12:36PM ET on Tuesday Nov 05, 2024 by Dow Jones
12:36PM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 4, 2024
*DJ TG Therapeutics 3Q EPS 2c >TGTX, from 7:00AM ET on Monday Nov 04, 2024 by Dow Jones
7:00AM ET on Monday Nov 04, 2024 by Dow JonesTG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI(R) (ublituximab-xiiy) Full Year Revenue Guidance, from 7:00AM ET on Monday Nov 04, 2024 by Dow Jones
7:00AM ET on Monday Nov 04, 2024 by Dow Jones
Nov 1, 2024
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update, from 8:06AM ET on Friday Nov 01, 2024 by Dow Jones
8:06AM ET on Friday Nov 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TG Therapeutics Inc | 4.6B | -277.9x | --- |
ADMA Biologics Inc | 4.6B | 71.1x | --- |
Axsome Therapeutics Inc | 4.4B | -14.0x | --- |
Arcellx Inc | 4.7B | -119.8x | --- |
Blueprint Medicines Corp | 5.7B | -42.8x | --- |
CRISPR Therapeutics AG | 4.0B | -16.8x | --- |
Company Information
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Contact Information
- Headquarters
- 3020 Carrington Mill Blvd., Suite 475MORRISVILLE, NC, United States 27560-5435
- Phone
- 212-554-4484
- Fax
- 212-554-4531
Executives
- Chairman of the Board, President, Chief Executive Officer
- Michael Weiss
- Chief Financial Officer, Treasurer, Corporate Secretary
- Sean Power
- Lead Independent Director
- Laurence Charney
- Independent Director
- Yann Echelard
- Independent Director
- Kenneth Hoberman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.6B |
|---|---|
Revenue (TTM) | $264.8M |
Shares Outstanding | 154.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.19 |
EPS | $-0.11 |
Book Value | $1.06 |
P/E Ratio | -277.9x |
Price/Sales (TTM) | 17.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -0.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
